https://www.selleckchem.com/JAK.html
about the adiponectin paradox, which were recently described in basic, epidemiologic, and clinical studies. Interleukin-1β (IL-1β) is an important pathogenic factor in cardiovascular diseases including chronic heart failure (HF). The CANTOS trial highlighted that inflammasomes as primary sources of IL-1 β are promising new therapeutic targets in cardiovascular diseases. Therefore, we aimed to assess inflammasome activation in failing hearts to identify activation patterns of inflammasome subtypes as sources of IL-1β. Out of the 4 major inflammasome
Like
Comment
Share
